Viking Therapeutics presents positive Phase 2 data on VK2735 obesity drug at European Congress on Obesity

Viking Therapeutics announced it will present two posters at the 33rd European Congress on Obesity highlighting data from its Phase 2 trial of VK2735, an oral and subcutaneous dual GLP-1/GIP receptor agonist for obesity treatment. The Phase 2 VENTURE-Oral trial showed significant weight loss and good tolerability over 13 weeks. Additionally, Viking shared enrollment details of the ongoing Phase 3 VANQUISH-1 trial targeting adults with obesity or overweight with related health issues. These presentations mark important steps in VK2735's clinical development, with further data expected from the Phase 3 study.